" class="no-js "lang="en-US"> News Archives - Page 52 of 267 - Medtech Alert
Friday, September 26, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure […]

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing […]

Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

Morphimmune, a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment […]

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

PureTech Health, a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, […]

Medtronic to Boost AI Innovation with New Platform Introduction

Medtronic, a global leader in healthcare technology, has announced Cosmo Pharmaceuticals and NVIDIA plan to […]

Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS

Ionis has announced the outcome of the United States Food and Drug Administration’s (FDA) Peripheral […]

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Massive Bio, a private AI-enabled oncology startup that provides virtual and in-person concierge services for […]

Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new data […]

Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel

Capstan Therapeutics, a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted […]

PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate

PeptiDream, a public Kanagawa, Japan-based biopharmaceutical company, has today announced the nomination of the second […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more